Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - ScienceDirect
Les thérapies HER2 pour les patients atteints de mCCR
p95HER2–T cell bispecific antibody for breast cancer treatment | Science Translational Medicine
The HER family as therapeutic targets in colorectal cancer - ScienceDirect
Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer
Comprehensive assessment of HER2 alteration in a colorectal cancer coh | CMAR
Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer | Virchows Archiv
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
Pathology Outlines - HER2 colon
Anti-HER2 Agents Gain Ground in Colorectal Cancer
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models | Journal of Experimental & Clinical Cancer Research | Full Text
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-5-2x.jpg "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
HER2 expression and copy number alterations in colorectal cancer (CRC).... | Download Scientific Diagram
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-1-full.png "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer
Fulfilling the potential of HER2-targeting in colorectal cancer: update on detection and management - YouTube
Pathology Outlines - HER2 colon
EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer | Scientific Reports
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology
